Moleculin Biotech Inc (MBRX)vsModerna Inc (MRNA)
MBRX
Moleculin Biotech Inc
$0.77
-0.88%
HEALTHCARE · Cap: $16.16M
MRNA
Moderna Inc
$154.04
-2.55%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
MBRX leads profitability with a 0.0% profit margin vs -141.4%. MBRX earns a higher WallStSmart Score of 23/100 (F).
MBRX
Avoid23
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MBRX.
Margin of Safety
+69.9%
Fair Value
$134.69
Current Price
$154.04
$19.35 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 9.1x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MBRX
The strongest argument for MBRX centers on P/E Ratio, Price/Book, Debt/Equity.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : MBRX
The primary concerns for MBRX are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
MBRX profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
MBRX carries more volatility with a beta of 1.92 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
MBRX generates stronger free cash flow (-7M), providing more financial flexibility.
Bottom Line
MBRX scores higher overall (23/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moleculin Biotech Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant viruses and tumors in the United States. The company is headquartered in Houston, Texas.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?